EdRIP raises €125m for fourth life sciences fund

EdRIP is aiming to close the fund on €200m by the end of the year.

Its precursor, BioDiscovery 3, was launched in February 2008 and held a final close in May of the same year on €150m.

Management fee, carry and hurdle correspond to industry standards.

Investors
Commitments for BioDiscovery 4 came from both existing and new institutional investors, with existing investors contributing more than half of the commitments.

Investments
The fund aims to lead investments in 15-20 life sciences companies, such as therapeutic drug development businesses and medical technology and molecular diagnostics companies. The investments will not depend on the development stage of the target and will take place across Europe.

While regions will be targeted on a deal-by-deal basis and the balanced deployment of capital between countries will be kept in mind, it is most likely that France will play the biggest role in terms of target locations.

People
BioDiscovery 4 will be managed by a team led by EdRIP's Gilles Nobécourt, Raphael Wisniewski and Olivier Litzka.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Venture
• France
• Healthcare
• France
• Venture